Pieris appoints chief scientific officer

Joins German firm from Merck & Co bringing therapeutic protein drug development expertise

Laurent Audoly has joined Pieris as chief scientific officer. Audoly, most recently Biologics Research Site Lead at Merck & Co, brings both pharma and biotech experience to the German biotechnology company, particularly expertise in therapeutic protein drug development.

‘Laurent’s pharmacology expertise and drug development skills are the precise ingredients we need to maximise the value of our growing therapeutic pipeline,’ saidd Stephen Yoder, chief executive of Pieris.

‘As the company builds and expands its internal and partnered Anticalin pipeline, Laurent's contribution will be significant.’

You may also like

Regulatory

Commercialised anticalin inhaled treatments

Pieris Pharmaceuticals and AstraZeneca collaborate to develop and commercialise treatments for respiratory diseases
Ingredients

Pieris announces first cancer immunotherapy collaboration

Agreement with Roche leverages proprietary Anticalin technology platform
Research & Development

Pieris Pharmaceuticals and the University of Melbourne receive grant

To advance Anticalin-based therapeutic for inhaled delivery to treat asthmatics
Ingredients

Zydus Cadila and Pieris to collaborate on anticalin development

Collaboration combines Pieris’s drug discovery and early development capabilities with Zydus’s expertise in biologics development, regulatory affairs and biologics manufacturing
Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications
Manufacturing

Precision under pressure

Why pharma manufacturing needs a harder look at weight control
Subscribe now